SCHEMBL4631690

SCHEMBL4631690

CCCC(=O)OC(=O)C(C)(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
HDAC3 O15379 4/20 0.36
HDAC1 Q13547 4/20 0.36
HDAC2 Q92769 4/20 0.36
HDAC8 Q9BY41 4/20 0.36
FFAR3 O14843 3/20 0.36
LMNA P02545 1/20 0.35
PRSS1 P07477 1/20 0.35
CTSG P08311 1/20 0.35
CTRB1 P17538 1/20 0.35
CMA1 P23946 1/20 0.35
TSHR P16473 2/20 0.35
HDAC6 Q9UBN7 1/20 0.32
ELANE P08246 2/20 0.31
PRKCA P17252 1/20 0.31
NAAA Q02083 1/20 0.31
DGKA P23743 1/20 0.31
CTSD P07339 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22518718 0.96 ALDH1A1 (0.58) ALDH1A1CES2CES1HDAC3HDAC1
SCHEMBL6879249 0.86 ALDH1A1 (0.46) ALDH1A1CES2CES1LMNAPRSS1
SCHEMBL6899017 0.85 DGKA (0.50) ALDH1A1CES2CES1LMNATSHR
SCHEMBL28365907 0.84 ALDH1A1 (0.61) ALDH1A1CES2CES1HDAC3HDAC1
SCHEMBL385084 0.84 ALDH1A1 (0.61) ALDH1A1CES2CES1HDAC3HDAC1
SCHEMBL18126434 0.83 TSHR (0.40) ALDH1A1LMNATSHRELANEPRKCA
SCHEMBL31155339 0.83 DGKA (0.53) ALDH1A1CES2CES1LMNATSHR
SCHEMBL8882128 0.83 DGKA (0.53) ALDH1A1CES2CES1LMNATSHR
SCHEMBL8883996 0.83 DGKA (0.53) ALDH1A1CES2CES1LMNATSHR
SCHEMBL29126817 0.83 DGKA (0.53) ALDH1A1CES2CES1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207410-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF NEURODERM, LTD. (IL) 2024-06-27 US disclosed
EP-4305049-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF Neuroderm Ltd (IL) 2024-01-17 EP disclosed
US-11844754-B2 Methods for treatment of Parkinson's disease NEURODERM, LTD. (IL) 2023-12-19 US disclosed
CN-116964069-A Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof 纽罗德姆有限公司 2023-10-27 CN disclosed
WO-2023126945-A1 METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE NEURODERM, LTD. (IL) 2023-07-06 WO disclosed
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE NEURODERM, LTD. (IL) 2023-05-25 US disclosed
CN-110234623-B Solution containing dialkylzinc and dialkylzinc partial hydrolysate, and method for producing zinc oxide thin film using same 东曹精细化工株式会社 2023-04-18 CN disclosed
EP-4025200-A1 LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF Neuroderm Ltd (IL) 2022-07-13 EP disclosed
CN-114727973-A Liquid compositions comprising L-dopa amino acid conjugates and uses thereof 纽罗德姆有限公司 2022-07-08 CN disclosed
WO-2021044420-A1 LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF NEURODERM, LTD. (IL) 2021-03-11 WO disclosed
EP-1480640-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-01 EP disclosed
WO-2003072100-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-04 WO disclosed
EP-1250342-A1 BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS Polimeri Europa S.p.A. (IT) 2002-10-23 EP disclosed
WO-2001040238-A1 BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS POLIMERI EUROPA S.P.A. (IT) 2001-06-07 WO disclosed
CN-1045433-C Synthesis of colour negative yellow double-equivalent colour coupler CHANGCHUN APPLIED CHEMISTRY (CN) 1999-10-06 CN disclosed
CN-1114647-A Synthesis of colour negative yellow double-equivalent colour coupler CHANGCHUN APPLIED CHEMISTRY (CN) 1996-01-10 CN disclosed
US-5021330-A Light sensitive silver halide emulsion layer AGFA GEVAERT AKTIENGESELLSCHAFT (DE) 1991-06-04 US disclosed
EP-0216385-A2 Antibacterial compounds Takeda Chemical Industries, Ltd. (JP) 1987-04-01 EP disclosed
US-4609620-A CHROMOGENIC MONOCHROME NEGATIVES CIBA GEIGY AG (CH) 1986-09-02 US disclosed
EP-0089315-A2 Pyrazolone compounds and a process for their manufacture CIBA-GEIGY AG (CH) 1983-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11844754-B2 Methods for treatment of Parkinson's disease DDC, DDT, SLC6A3 ALDH1A1 609/4885CES2 382/4885CES1 1777/4885
US-20240207410-A1 STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF COMT, TH, DDT ALDH1A1 398/4885CES2 432/4885CES1 1838/4885
US-20230157985-A1 METHODS FOR TREATMENT OF PARKINSON'S DISEASE DDC, DDT, COMT ALDH1A1 590/4885CES2 360/4885CES1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.